Market revenue in 2023 | USD 1,562.3 million |
Market revenue in 2030 | USD 3,876.2 million |
Growth rate | 13.9% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.88% in 2023. Horizon Databook has segmented the Asia Pacific immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
The need for early diagnosis of neurological diseases to reduce treatment costs & mortality is expected to fuel market demand in Asia Pacific. Increasing healthcare investments in countries, such as China and India, is also positively influencing market growth.
The abundance of raw materials for manufacturing immunoassay products can increase manufacturer interest. POC diagnostics and personalized medicines are expected to drive the Asia Pacific market, supported by the regional presence of major manufacturers and market demand for cost-effective tests & diagnostic options.
Development of technologically advanced products or immunoassay devices, with improved accuracy, sensitivity, and precision, requires intensive seed capital. The financial burden may restrain the market growth, especially in economically weaker sections of this region.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific immunoassay for neurological biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account